• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Hodgkin lymphoma - Articles and news items

NICE asks BMS for more data before approving cancer drug

Industry news / 24 March 2017 / Niamh Marriott, Junior Editor

NICE has asked Bristol Myers Squibb, who manufacture nivolumab (Opdivo), to provide more information on its effectiveness for treating Hodgkin lymphoma…

Five-year data from Phase II trial of Adcetris published

Industry news / 19 July 2016 / Victoria White, Digital Content Producer

The data comes from a Phase II trial of Adcetris (brentuximab vedotin) in patients with relapsed or refractory classical Hodgkin lymphoma…

First-in-human trial of MundiPharma’s EDO-S101 starts

Industry news / 14 July 2016 / Victoria White, Digital Content Producer

A first in class, fusion molecule, S101 is currently being developed for the treatment of relapsed-refractory haematological malignances…

EC extends conditional marketing authorisation for Adcetris

Industry news / 6 July 2016 / Victoria White, Digital Content Producer

The EC has extended the current conditional marketing authorisation of Adcetris as consodlidation treatment in post-transplant Hodgkin lymphoma…

Positive CHMP opinion for Adcetris in post-transplant Hodgkin lymphoma

Industry news / 27 May 2016 / Victoria White, Digital Content Producer

The opinion is for Adcetris for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following ASCT…

FDA accepts sBLA for Opdivo in classical Hodgkin Lymphoma

Industry news / 15 April 2016 / Victoria White, Digital Content Producer

The FDA has accepted a sBLA for Opdivo that seeks to expand the use of the therapy to patients with Hodgkin Lymphoma after prior therapies…

Keytruda and AFM13 to be investigated in Hodgkin lymphoma

Industry news / 25 January 2016 / Victoria White

The purpose of the study is to establish a dosing regimen for this combination therapy and assess its safety and efficacy…

Hodgkin’s lymphoma treatment market to hit $1.4b by 2024, says GlobalData

Industry news / 19 January 2016 / Victoria White

GlobalData says the impressive growth in the market will be attributable to label extensions for Seattle Genetics’ Adcetris and the launch of new therapies for relapse or refractory Hodgkin’s lymphoma…